94924-94-4

Basic information

• Product Name: 5-(piperidin-1-yl)pyridin-2-amine
• Synonyms: 5-(piperidin-1-yl)pyridin-2-amine;2-Pyridinamine,5-(1-piperidinyl)-
• CAS NO: 94924-94-4
• Molecular Formula: C₁₀H₁₅N₃
• Molecular Weight: 177.2462
• Mol File: 94924-94-4.mol
• Article Data: 25

Chemical Properties

• Boiling Point: 363.1±27.0 °C(Predicted)
• Appearance: /
• Density: 1.127±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 7.46±0.26(Predicted)
• CAS DataBase Reference: 5-(piperidin-1-yl)pyridin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(piperidin-1-yl)pyridin-2-amine(94924-94-4)
• EPA Substance Registry System: 5-(piperidin-1-yl)pyridin-2-amine(94924-94-4)

Safety Data

• Hazardous Substances Data: 94924-94-4(Hazardous Substances Data)

Usage

General Description

5-(piperidin-1-yl)pyridin-2-amine is a chemical compound with the molecular formula C11H15N3. It is a derivative of pyridine and has a piperidine group attached to the 5th position. 5-(piperidin-1-yl)pyridin-2-amine has potential application in pharmaceutical research due to its structural features and potential biological activity. The piperidine group is known to be a common pharmacophore in many drug molecules, and the presence of the pyridine ring also gives it potential as a scaffold for developing new drugs. Its properties and potential uses make it an interesting compound for further study and research in the fields of medicinal chemistry and drug development.

Upstream product

• 39856-50-3 5-bromo2-nitropyridine 
• 110-89-4 piperidine 
• 444146-17-2 6'-nitro-3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl 

Downstream Products

• 1198408-75-1 C₁₉H₁₉ClN₄O 
• 571190-09-5 [8-cyclopentyl-7-oxo-2-(3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl-6'-ylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidin-6-ylmethyl]-carbamic acid benzyl ester 

Relevant articles and documents

DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS

A novel class of heteroaryl compounds for use in the prevention and/or treatment of proliferative diseases and conditions including cancers. The compounds are considered to be capable of inhibiting cell proliferation by inhibiting the activity of FLT3 and its mutant forms and/or other protein kinases such as CDKs. The compounds have the general structure I:

Discovery and SARs of 5-Chloro- N4-phenyl- N2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives as Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity

Cyclin-dependent kinases (CDKs) are promising therapeutic targets for cancer therapy. Herein, we describe our efforts toward the discovery of a series of 5-chloro-N4-phenyl-N2-(pyridin-2-yl)pyrimidine-2,4-diamine derivatives as dual CDK6 and 9 inhibitors. Intensive structural modifications lead to the identification of compound 66 as the most active dual CDK6/9 inhibitor with balancing potency against these two targets and good selectivity over CDK2. Further biological studies revealed that compound 66 was directly bound to CDK6/9, resulting in suppression of their downstream signaling pathway and inhibition of cell proliferation by blocking cell cycle progression and inducing cellular apoptosis. More importantly, compound 66 significantly inhibited tumor growth in a xenograft mouse model with no obvious toxicity, indicating the promising therapeutic potential of CDK6/9 dual inhibitors for cancer treatment. Therefore, the above results are of great importance in the development of dual CDK6/9 inhibitors for cancer therapy.

CDK INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISORDERS

This invention is in the area of pyrimidine-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to cancer that has developed resistance to other CDK4/6 inhibitors.